MedPath

A 1-Year Safety Study of OTO-104 in Subjects With Unilateral Meniere's Disease Located in United Kingdom

Phase 2
Completed
Conditions
Meniere's Disease
Interventions
Drug: Placebo
Registration Number
NCT02265393
Lead Sponsor
Otonomy, Inc.
Brief Summary

This is a 2-part study of OTO-104 in subjects with unilateral Meniere's disease in the United Kingdom. The first part is a randomized, placebo-controlled study comparing the safety profile of 2 injections of OTO-104 or placebo spaced 3 months apart. The second part is an open-label extension where all subjects will receive an additional 2 intratympanic injections of OTO-104 spaced 3 months apart. Each subject will participate on the study for a total of 1 year.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
128
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPlaceboOTO-104 vehicle
OTO-104OTO-10412 mg OTO-104 (dexamethasone)
Primary Outcome Measures
NameTimeMethod
SafetyUp to 1 Year

Otoscopy, audiometry, tympanometry, adverse events

Secondary Outcome Measures
NameTimeMethod
Meniere's Symptom QuestionnaireUp to 1 Year

Trial Locations

Locations (15)

Heatherwood & Wexham Park Hospitals

🇬🇧

Berkshire, United Kingdom

Birmingham University Hospital

🇬🇧

Birmingham, United Kingdom

BMI The Edgbaston Hospital

🇬🇧

Birmingham, United Kingdom

Southmead Hospital Bristol

🇬🇧

Bristol, United Kingdom

Oxford University Hospitals

🇬🇧

Bucks, United Kingdom

Cambridge University Hospitals

🇬🇧

Cambridge, United Kingdom

Dorset County Hospital

🇬🇧

Dorset, United Kingdom

Gloucestershire Royal Hospital

🇬🇧

Gloucester, United Kingdom

Leicester Royal Infirmary

🇬🇧

Leicestershire, United Kingdom

Guy's Hospital and St. Thomas' Hospital

🇬🇧

London, United Kingdom

Scroll for more (5 remaining)
Heatherwood & Wexham Park Hospitals
🇬🇧Berkshire, United Kingdom

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.